Pfizer, the No. 1 U.S. drugmaker, reported fourth-quarter earnings Tuesday that exceeded analysts’ estimates for both profit and sales. Despite the earnings beat, Pfizer is facing some tough challenges. There’s little clarity on how the company plans to overcome the loss of patent protection on some top drugs, and it’s struggling to find top-line growth.